Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Evaluable Disease

Known as: Evaluable 
Disease that cannot be measured directly by the size of the tumor but can be evaluated by other methods specific to a particular clinical trial.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
BACKGROUND Paediatric low-grade glioma is the most common CNS tumour of childhood. Although overall survival is good, disease… Expand
Review
2019
Review
2019
Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
BACKGROUND A solitary fibrous tumour is a rare soft-tissue tumour with three clinicopathological variants: typical, malignant… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Review
2019
Review
2019
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study
Abstract Background NTRK1, NTRK2 and NTRK3 gene fusions (NTRK gene fusions) occur in a range of adult cancers. Larotrectinib is a… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
Review
2019
Review
2019
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.
INTRODUCTION Durvalumab selectively blocks programmed cell death ligand-1 (PD-L1) binding to programmed cell death-1. Encouraging… Expand
Review
2019
Review
2019
A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential
  • C. White
  • Journal of clinical pharmacology
  • 2019
    • Corpus ID: 73452711
Cannabidiol (CBD) is a highly touted product for many different disorders among the lay press. Numerous CBD products are… Expand
Review
2018
Review
2018
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome
This article summarizes key review findings that supported the approval of tocilizumab for treatment of severe or life… Expand
  • table 1
  • table 2
  • table 3
Review
2018
Review
2018
Implementing Measurement-Based Care in Behavioral Health: A Review
Importance Measurement-based care (MBC) is the systematic evaluation of patient symptoms before or during an encounter to inform… Expand
  • table 1
  • table 3
Review
2018
Review
2018
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study
Importance Effective treatment options are limited for patients with advanced, metastatic esophageal cancer progressing after 2… Expand
  • table 2
  • table 1
  • figure 1
  • table 1
  • table 2
Review
2018
Review
2018
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
Background MET exon 14 alterations are actionable oncogenic drivers. Durable responses to MET inhibitors are observed in patients… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Review
2017
Review
2017
Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma
The purpose of this study was to evaluate 18F-FDG PET/CT scanning as an early predictor of response to immune checkpoint… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 2
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE